Moderna, Merck Skin Cancer Vaccine Cuts Risks of Death in Trial
December 13, 2022
5,097
96
23
2.33%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Bloomberg Television Episodes Around December 13, 2022
See what was published immediately before and after this episode.
9:41Now PlayingModerna, Merck Skin Cancer Vaccine Cuts Risks of Death in Trial
YouTube Description
as posted by the channelModerna Inc.'s experimental personalized cancer vaccine reduced the risk of relapse or death from melanoma when combined with Merck & Co.'s Keytruda in a mid-stage trial. The combination cut the death risk or recurrence of the skin cancer by 44%. cut The drugmakers want to move into final-stage studies next year. Moderna CEO Stephane Bancel speaks with Bloomberg's Guy Johnson and Alix Steel.
Follow Bloomberg for business news & analysis, uptotheminute market data, features, profiles and more
Connect with us on...
Links & Promotions
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.